Clinical Trials Logo

Clinical Trial Summary

This pilot phase 0 trial studies accelerated hypofractionated radiation therapy immediately before surgery in treating patients with malignant pleural mesothelioma (cancer in the thin layer of tissue that covers the lungs and lines the interior wall of the chest cavity). Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Hypofractionated radiation therapy is a type of radiation therapy in which the total prescribed dose of radiation is divided into fewer but larger doses as compared to conventional radiation therapy. Giving accelerated hypofractionated radiation therapy immediately before surgery may improve survival, and may also reduce side effects experienced by patients with pleural mesothelioma.


Clinical Trial Description

PRIMARY OBJECTIVES:

I. To determine the feasibility and toxicity (both acute and chronic) of accelerated hypofractionated neoadjuvant helical intensity modulated radiation therapy prior to pleurectomy/decortication for malignant pleural mesothelioma.

SECONDARY OBJECTIVES:

I. To determine the pathologic complete response rate (pCR). II. To determine the tumor local control rate (LC). III. To determine the malignant pleural mesothelioma disease specific survival (DSS).

IV. To determine the overall survival (OS). V. To assess transforming growth factor beta (TGF-B), interleukin (IL)-1, and IL-6 levels as predictive biomarkers for treatment induced tissue injury.

VI. To assess the changes in the postoperative pleural immunological milieu in terms of chemo- and cytokine expression.

OUTLINE:

Patients undergo 5 fractions of accelerated hypofractionated intensity-modulated radiation therapy (IMRT) over 1 week with simultaneous integrated boost to gross disease. Patients then undergo pleurectomy/decortication within 14 days after completion of IMRT.

After completion of study treatment, patients are followed up at 6 weeks, and then every 3 months for 5 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02672033
Study type Interventional
Source Jonsson Comprehensive Cancer Center
Contact
Status Terminated
Phase N/A
Start date September 1, 2015
Completion date July 17, 2018

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03126630 - Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma Phase 1/Phase 2
Active, not recruiting NCT02959463 - Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma Phase 1
Active, not recruiting NCT02399371 - Pembrolizumab in Treating Patients With Malignant Mesothelioma Phase 2
Active, not recruiting NCT01064648 - Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma Phase 1/Phase 2
Recruiting NCT03290183 - Confocal Laser Endomicroscopy in Pleural Malignancies N/A
Completed NCT01112293 - Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma Phase 2